Compare Erasca Inc. Common Stock (ERAS) vs Eversource Energy (D/B/A) Common Stock (ES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Eversource Energy (D/B/A) Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Eversource Energy (D/B/A) Common Stock trades at $66.63 (market cap $24.77B). The key difference: Eversource Energy (D/B/A) Common Stock is far larger — about 4.8× Erasca Inc. Common Stock's market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.79% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Eversource Energy (D/B/A) Common Stock for 0 Days on average.
| ERAS | ES | |
|---|---|---|
Market Cap | $5.17B | $24.77B |
Volume | 5,313,379 | 3,738,127 |
Sector | Health | Utilities |
52-Week High | $22.47 | $76.21 |
52-Week Low | $2.20 | $63.28 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $54.84B |
Dividend Yield | — | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →
